Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828652) titled 'Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)' on Sept. 2.
Study Type: Observational
Primary Sponsor: Yeon Hee Park
Condition:
TNBC - Triple-Negative Breast Cancer
Intervention:
Other: Medical record use research
Recruitment Status: Not recruiting
Date of First Enrollment: September 14, 2026
Target Sample Size: 2000
To know more, visit https://clinicaltrials.gov/study/NCT07828652
Disclaimer: Curated by HT Syndication....